Review

Current and emerging biological therapy in adult-onset Still’s disease

Yuning Ma, Jianfen Meng, Jinchao Jia, Mengyan Wang, Jialin Teng, Dehao Zhu, Chengde Yang and Qiongyi Hu

Abstract

Adult-onset Still’s disease (AOSD) is a rare, but characteristic non-familial, multi-genic systemic auto-inflammatory disorder, characterized by high spiking fever, salmon-like evanescent skin rash, polyarthritis, sore throat, hyperferritinemia and leucocytosis. The hallmark of AOSD is a cytokine storm triggered by dysregulation of inflammation. Nowadays, with advances in anti-cytokine biologic agents, the treatment of AOSD is no longer limited to NSAIDs, glucocorticoids or conventional synthetic DMARDs. In this review, we focussed on the roles of these cytokines in the pathogenesis of AOSD and summarized the current and emerging biological therapy.

Key words: adult-onset Still’s disease, cytokine storm, biological therapy

Introduction

Adult-onset Still’s disease (AOSD) is a rare, non-familial, multi-genic auto-inflammatory disorder with multisystem involved. The incidence is estimated between 0.16 and 0.4/100,000 persons in different ethnic groups [1–3]. Patients with AOSD often suffer from high spiking fever, salmon-like evanescent skin rash, polyarthritis, sore throat, hyperferritinemia and leucocytosis. More importantly, the mortality is high due to severe life-threatening complications, including macrophage activation syndrome (MAS) and fulminant hepatitis [4,5]. In 1897, Sir George Still reported for the first time 22 children whose symptoms were similar to systemic onset of JIA (SOJIA) [6]. In 1971, Bywaters analysed 14 adult patients with similar clinical manifestations to SOJIA and named this independent disease as AOSD [7]. Due to heterogeneous clinical features and rarity of randomized controlled studies of this disease, therapy is usually empiric-al. Nowadays, rheumatologists still face a great challenge in therapy of AOSD despite a large swathe of new drugs. Herein, the most recent progress in the biological treatment of AOSD is reviewed.

Pathogenesis

Based on the different clinical courses, AOSD can be classified into three distinct patterns, including a monocylic course, a polycyclic course and a chronic course. To better make a therapeutic strategy, AOSD phenotype can be dichotomized in systemic form and chronic ar-ticular form instead of these three patterns [5,8,9]. The hallmark of AOSD pathogenesis is cytokine storm, characterized by excessive production of IL-1β, IL-18, IL-6, IL-10, IFN-γ, TNF and other cytokines [10]. No single definition of cytokine storm in AOSD is widely accepted nowadays; we define the cytokine storm in AOSD as a persisting and chronic self-sustaining cytokine and cellular stimulation, of which the dominant cytokines can be changed due to different clinical phenotypes. IL-1β, IL-18, IFN-γ, IL-4 and IL-10 are believed to be more...
associated with systemic form, whereas IL-6, TNF, IL-17 and IL-23 are more associated with chronic arthritic form [11–13]. Secreted by hyperactivated neutrophils and macrophages, these inflammatory mediators further activate other immune cells (such as helper T (Th)1 and Th17 cells), leading to uncontrollable inflammatory cascade [14–17]. There is accumulating evidence that infectious triggers can initiate a complicated inflammatory cascade in AOSD with certain genetic susceptibility (Fig. 1).

**A cytokine storm**

Inappropriate activation of the innate immune cells (mainly macrophage and neutrophil) is recognized as the first line of formation of cytokine storm in AOSD. Both pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), including S100 proteins, soluble CD163, high mobility group box-1, advanced glycation end products, macrophage inhibitory factor (MIF) and neutrophil extracellular traps (NETs) can activate macrophages and neutrophils via specific Toll-like receptors (TLRs), then NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasomes are excessively activated [5, 18–21]. Thus, the activity of caspase-1 is upregulated, leading to forming bioactive IL-1β and IL-18 [20]. After that, innate and adaptive immune cells are intensely activated, leading to exuberant production of pro-inflammatory cytokines induced by IL-1β and IL-18, including IL-6, IL-8, IL-17 and tumour necrosis factor TNF, as well as IL-1β and IL-18 themselves, generate the burst of a cytokine storm. Besides, neutrophils, Th17 cells, Th1 cells and NK cells also contribute to the burst of the cytokine storm. Targeted therapy for the treatment of AOSD is at IL-1β or IL-1R with anakinra, canakinumab or rilonacept, at IL-18 with tadekinig alfa, at IL-6R with tocilizumab or sarilumab, and at TNF-α or TNFR2 with infliximab, adalimumab or etanercept, at CD20 with rituximab, at CD80/CD86 with abecabac, at JAK with tofacitinib or baricitinib or at GM-CSF or GM-CSFR with mavrilimumab or golimumab. AOSD: adult-onset Still's disease; DAMP: damage-associated molecular pattern; NK: natural killer; NLRP3: NACHT, LRR and PYD domains-containing protein 3; PAMP: pathogen-associated molecular pattern.
T cells also contribute to the pathogenesis of AOSD. Increased levels of circulating Th1 cells and Th17 cells, and decreased levels of circulating CD4⁺CD25⁺ Treg cells were found in active AOSD patients [27–29]. Th1 cells produce IFN-γ, regulating the recruitment of macrophages, and Th17 cells produce IL-17, which may induce the production of IL-6 and IL-8 [30,31].

Aside from amplified inflammatory cascade, it’s hypothesized that deficient resolution of inflammation also plays a role in the cytokine storm of AOSD. The typical anti-inflammatory cytokines IL-10 and IL-37 are also plays a role in the cytokine storm of AOSD. The hypothesis that deficient resolution of inflammation may partly quell the ab-
cical anti-inflammatory cytokines IL-10 and IL-37 can induce the polarization of anti-inflammatory macrophages, which help with resolving the exaggerated inflammatory response [38,39].

Genetic background

No evidence has shown that family aggregation has appeared in the occurrence of AOSD, but previous studies have revealed an association between genetic susceptibility and gene polymorphisms of the HLA, including HLA-Bw35, -B17, -B18, -B35, -DR2, -DR4, -DR5, -DG1, Dw6, -DRB1 and -DQB1 [40–44]. A genome-wide association study was conducted for the first time to systematically screen genetic factors influencing susceptibility to AOSD in a Chinese multicentre cohort, consisting of 264 AOSD cases and 2420 controls. This finding identified that both HLA class I and II regions are susceptibility loci for AOSD [45]. Polymorphisms in the non-HLA regions encoding IL-6, IL-18, serum amyloid A, MIF and MEFV also contribute to the susceptibility of AOSD patients [46–50]. Recently, functional leucocyte immunoglobulin-like receptor A3 (LILRA3) has been reported to be a novel genetic susceptibility factor for AOSD [51].

Infectious triggers

There is a popular belief that infection trigger is the main driver of inflammatory response of AOSD. The outbreak of COVID-19, a novel virus-induced severe respiratory disease with high mortality rate has brought attention to the pathogenetic role of viral infections as inflammatory triggers in cytokine storm. The similarities of clinical manifestations between viral infections and AOSD – such as acute-onset, high spiking fever and sore throat – have often been remarked on [10]. Unlike the classical cytokine storm with systemic inflammatory response, the cytokine storm triggered by SARS-CoV-2 infection leads to organ-specific dysfunction, characterized by intra-pulmonary macrophage activation and thrombotic lesions formation. The cytokine panel between severe COVID-19 and active AOSD is different, as our previous study reports [10, 52]. Some studies have found the presence of anti-viral antibody and viral DNA in active AOSD patients. Besides viral infections, bacterial infections have been reported to be accompanied by the onset of AOSD, due to the potential to initiate inflammatory response by TLRs activation [5, 19, 53–58].

Treatment

In the past, the treatment of AOSD was a tough task with limited therapeutic options to nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Glucocorticoids remain the mainstay treatment of AOSD, and DMARDs are often required in some patients with poor response to glucocorticoids. Around 17–32% of AOSD patients are resistant to both first-line corticosteroids and second-line DMARDs in some observational studies, and this group of patients are uniformly called ‘refractory AOSDs’ [59–63]. Nowadays, with the success of targeted biological treatments in rheumatic diseases, the management of AOSD has been revolutionized, especially in the refractory forms (Fig. 2).

IL-1β and its inhibitors

IL-1β is the most frequently studied and well characterized member of the IL-1 superfamily. Secreted mostly by myeloid cells, IL-1β activates granulocytes, Th17 cells and innate lymphoid cells (ILC3), leading to tissue inflammation and injury. The pathogenic role of IL-1β has been involved in rheumatic and auto-inflammatory diseases, including RA, gout, cryopyrin-associated periodic syndromes, SOJIA and AOSD [64,65]. Activation of IL-1β is mediated by inflammasome-dependent means in monocytes/macrophages and inflammasome-independent means in neutrophils. After engagement of pattern recognition receptors (PRRs), transcription of IL1B mRNA is induced and translated to a biologically inert precursor, pro-IL-1β. Pro-IL-1β is stored in the cytosol of activated monocytes/macrophages and gains its biological activity after the cleavage of its amino-terminal pro-peptide with caspase-1 depending on the assembly of inflammasome complexes [65]. Then, mature IL-1β will be released into extracellular space and bind to IL-1 receptor 1 (IL-1R1) on target cells. The intracellular signalling molecules of IL-1β will be provoked, including myeloid differentiation factor 88, IL-1 receptor-associated kinase 4 (IRAK4) and TNF receptor-associated factor 6, resulting in activation of nuclear factor κB (NF-κB) and p38, as well as c-Jun-N-terminal kinase, extracellular signal-regulated kinase and mitogen-activated protein kinases [65].

This signalling activated by IL-1β will lead to the production of various pro-inflammatory mediators, including IL-6, IL-8, TNF and many chemokines, followed by the attraction of macrophages, neutrophils and ILC3 capable of secreting IL-17 and IL-22. Besides, IL-1β is also a key cytokine to promote adaptive immunity. IL-1β supports the differentiation of CD4⁺ T cells into pro-
inflammatory T cell populations, including Th1 and Th17 cells, and it can induce expansion and differentiation of antigen-specific CD8$^+$ T cells as well [66,67].

As a potent pro-inflammatory mediator, IL-1β plays a fundamental role in the initiation and amplification of cytokine storm in AOSD. Increased levels of NLRP3 inflammasome, caspase-1 and IL-1β have been found in peripheral blood mononuclear cells (PBMCs) of AOSD patients, and NLRP3 inhibitor decreased the protein expressions of NLRP3 and IL-1β in PBMCs from AOSD patients [20]. As the role of IL-1β in the pathogenesis of AOSD is gradually unveiled, therapeutic inhibition of IL-1β has already become an established target in AOSD. Three IL-1-targeted biologics (anakinra, canakinumab and rilonacept) have been approved so far [68].

**Anakinra**

Anakinra, a recombinant human IL-1 receptor antagonist, reduces the activity of IL-1α and IL-1β by competing their IL-1 receptor [69]. Anakinra have been proven effective and well-tolerated in some case series (Table 1). Based on data from clinical trials, anakinra has been approved for a licence extension to treat both SOJIA and AOSD by the European Medicines Agency.

The only randomized study was carried out among 22 patients with refractory AOSD aiming to evaluate the efficacy of anakinra vs DMARDs. More patients with anakinra treatment achieved remission than patients with DMARDs treatment [71]. A large number of retrospective observational studies have confirmed the efficacy of anakinra in treating AOSD. The largest retrospective observational study of IL-1 inhibitors in AOSD patients in Italy reported that anakinra was effective in improving all clinical and serological manifestations, and Pouchot’s score was found to be significantly reduced at all time points [78]. A meta-analysis including nine clinical studies suggested the potential of anakinra to reduce and even stop concomitant glucocorticoids without AOSD flares [79]. However, a randomized, multicentre, phase
| Drugs     | Author, year (refs) | Patient number | Treatment and dosage | Overall response                     | Follow-up duration (months) | Severe adverse events | Study character                      |
|-----------|---------------------|----------------|----------------------|--------------------------------------|-----------------------------|-----------------------|--------------------------------------|
| Anakinra  | Naumann L, 2010 [70] | 8              | ANK 100 mg/day (8)   | Sustained remission: 8 (100%)        | <12 (2)                     | 0                     | Retrospective observational study     |
|           | Nordström D, 2012 [71] | 12             | ANK 100 mg/day (12)  | Remission at 8 weeks: 7 (58.3%) Remission at 24 weeks: 6 (50%) Discontinued corticosteroids use: 3 (25%) | <12 (12)                   | Worsening of AOSD (lack of efficacy) (1) | Open randomized multicentre study     |
|           | Lequerre, 2008 [72]  | 15             | ANK 100 mg/day (15)  | Complete remission: 9 (60%) Partial remission: 2 (13.3%) No response: 2 (13.3%) Intolerance: 2 (13.3%) Stopped steroids use: 2 (13.3%) | <12 (6)                     | Varicella (1) | Retrospective observational study     |
|           | Laskari K, 2011 [73] | 25             | ANK 100 mg/day (25)  | Complete clinical response: 21 (84%) Partial clinical response: 3 (12%) No clinical response: 1 (4%) Stopped steroids use: 12 (48%) | <12 (7)                     | Severe urticarial reaction (3) Infection (7) | Retrospective case series             |
|           | Giampietro C, 2013 [74] | 28             | ANK 100 mg/day (28)  | Complete remission: 16 (57.1%) Partial remission: 8 (28.6%) Loss of efficacy: 4 (14.3%) | >12                         | 0                     | Retrospective case series             |
|           | Cavalli G, 2015 [60]  | 20             | ANK 100 mg/day (20)  | Complete response: 14 (70%) Partial response: 2 (10%) No response: 4 (20%) Decreased corticosteroids use: 8 (40%) | <12 (6)                     | Varicella-zoster virus reactivation (2) | Retrospective multicentre case series |
|           | Ortiz-Sanjuán F, 2015 [158] | 41             | ANK 100 mg/day (41)  | Improvement of symptoms: arthritis 87.8% to 41.5% skin rash 58.5% to 7.3% fever 78% to 14.6% lymphadenopathy 26.8% to 4.9% | <12 (14)                   | Severe cutaneous rash (2) Infection (2) | Retrospective open-label multicentre study |
|           | Colafrancesco S, 2017 [72] | 140            | ANK 100 mg/day (127) | Significantly reduced Pouchot’s score [mean score 5.5 (± 1.9), range 2–10, at baseline vs 1.1 (± 1.4), range 0–7, after 3 months; P < 0.001] Complete remission after 12 months: 15 (10.7%) Secondary inefficacy after 12 months: 11 (7.8%) Steroid therapy from 97.8% to 55.6% after 12 months (P < 0.001) | <12 (43)                   | Severe skin reactions (18) Infection (7) | Multicentre retrospective observational study |

(continued)
| Drugs         | Author, year (refs) | Patient number | Treatment and dosage                                | Overall response                                                                 | Follow-up duration (months) | Severe adverse events                               | Study character                                      |
|---------------|---------------------|----------------|----------------------------------------------------|---------------------------------------------------------------------------------|----------------------------|----------------------------------------------------|-----------------------------------------------------|
| Neél S, 2018  | [159] ANK 100 mg/day (5) | 5              | Response: 4 (80%)                                   | NA                                                                              | NA                         | Retrospective multicentre case series              |
| Canakinumab   | Colafrancesco S, 2017 [72] CAN 150 mg/8 weeks (4) | 4              | Complete remission: 1 (25%) Partial remission: 2 (50%) Loss of efficacy: 1 (25%) | <12 (1) 12 (3) | 0 | Multicentre retrospective observational study |
| Feist E, 2018 | [160] CAN 150 mg/4 weeks (29) | 29             | ACR ≥ 70 responses at day 15: 19 (65.5%) Improvements at day 85: 13/18 (72.2%) | <12 | MAS (3) | Pyrexia (1) Cytomegalovirus infection (2) |
| Kedor C, 2020 | [76] CAN 4 mg/kg/4 weeks (19) (maximum 300 mg) Placebo (17) | 35             | In the intention-to-treat analysis, reduction of the DAS28 (ESR) of >1.2: 66.7% (CAN) vs 41.2% (PBO) (P = 0.18) Significantly higher ACR 30%: 61% (CAN) vs 20% (PBO) (P = 0.033) Significantly higher ACR 50%: 50% (CAN) vs 6.7% (PBO) (P = 0.009) Significantly higher ACR 70%: 28% (CAN) vs 0% (PBO) (P = 0.049) | <12 | Increased liver enzymes (1) Patellofemoral pain syndrome (1) Deep vein thrombosis (1) Hypotonia (1) | Phase II, randomised, double-blind, placebo-controlled, multicentre investigator-initiated trial |

ANK, anakinra; CAN, canakinumab; MAS, macrophage activating syndrome; NA, not available; PBO, placebo.
study for evaluating the efficacy and safety of anakinra in treating AOSD has been terminated due to a lack of included patients (ClinicalTrials.gov Identifier: NCT03265132). Overall, anakinra seems to be not only effective in improving clinical and laboratory manifestations, but also likely to reduce the dosage of glucocorticoids.

Canakinumab

Canakinumab is a human monoclonal antibody against IL-1β [80]. Although only a handful of clinical trials with canakinumab were conducted on AOSD patients, canakinumab was approved by the EMA and Food and Drug Administration (FDA) for both SOJIA and AOSD in 2016 on the basis of the concept of the Still’s disease continuum [81]. A randomized, phase II study recruited 35 AOSD patients. Although the difference between the canakinumab group and the placebo group was not statistically significant due to the lower number of included patients, a higher response rate was observed in the canakinumab group [82]. The clinical symptoms and laboratory findings can be improved after the use of canakinumab in some trials (Table 1) [19, 78].

Rilonacept

Rilonacept (also known as IL-1 Trap), an IL-1α and β inhibitor, has an ability to ameliorate clinic manifestations and achieve a prolonged remission in refractory AOSD patients [83,84]. Experience with rilonacept has shown its effectiveness to both arthritic and systemic symptoms of refractory AOSD patients [84–86]. In a 24-month follow-up study, five refractory AOSD patients were treated with rilonacept; three of the five patients had meaningful clinical improvements [87]. Rilonacept is mostly used in patients with unsatisfied response to anakinra. Moreover, rilonacept is well-tolerated and has demonstrated efficacy in a randomized, placebo-controlled study of active SOJIA [88]. However, rilonacept hasn’t been licenced for use in AOSD either in Europe or the USA. In summary, treatment with IL-1 inhibitors leads to complete or partial remission in most AOSD patients.

IL-6 and its inhibitors

Although IL-6 is mostly regarded as a pro-inflammatory cytokine, it is considered to be pleiotropic due to its protective and regenerative functions on the grounds of different patterns of signalling [89]. IL-6 can be produced by neutrophils and monocytes/macrophages. The membrane-bound mIL-6Rα binds IL-6, and mIL-6Rα interacts with gp130 and thereby provokes signal transduction through the signal transducer and activator of transcription 3 (STAT3) and NF-κB pathway [90,91]. IL-6 can feed back in the control of neutrophil and monocyte responses. It is also a survival factor for lymphocytes [89,90, 92]. Moreover, IL-6 can drive polarization of CD4+ T cells towards Th17 cells [93,94]. It can lead to some pro-inflammatory effects, including typical manifestations of active AOSD, such as fever, arthritis, skin rash and elevated CRP. Not surprisingly, IL-6 level is significantly increased in both serum and cutaneous lesions of active AOSD patients. The clinical application experience of two IL-6 inhibitors (tocilizumab and sarilumab) have been achieved in AOSD.

Tocilizumab

Tocilizumab is a humanized anti-IL-6 receptor antibody that binds to both membrane-bound and soluble form of the IL-6 receptor. Izumoto et al. used tocilizumab for the first time in a refractory AOSD patients in 2002 with promising results [95]. Many previous reports have suggested that tocilizumab is effective in treating AOSD of both systemic and chronic articular forms (Table 2) [96, 98,99, 101–110]. In a pilot study in China, a combination of tocilizumab with DMARDs or glucocorticoids can partially improve clinical and laboratory manifestations of refractory AOSD patients and contribute to withdrawal of glucocorticoids [110]. The first randomized, phase III study included 27 patients with AOSD refractory to glucocorticoids in Japan. An improvement of clinical manifestation and a remarkable steroid-sparing effect was observed in most patients. Serious adverse events in the tocilizumab group included infections, exacerbation of AOSD, drug eruption, anaphylactic shock and aseptic necrosis in the hips. The study suggests that tocilizumab is effective and well-tolerated [102]. Moreover, some case reports have indicated that tocilizumab is effective for the treatment of AOSD-related systemic complications, including MAS, pulmonary arterial hypertension and thrombotic thrombocytopenic purpura [111–114].

Sarilumab

Sarilumab is an IL-6 receptor inhibitor. To our knowledge, the use of sarilumab in AOSD has been reported only once. The case report observed that sarilumab ameliorated clinical manifestations and spared corticoid in a 25-year-old male patient with cortico-dependent AOSD [115]. A post hoc analysis of the ASCERTAIN EXTEND (NCT01146652) trial suggests that switching tocilizumab non-responders to sarilumab may have favourable efficacy outcomes by investigating outcomes for tocilizumab non-responders completing ASCERTAIN (NCT01768572) who switched to sarilumab [116].

TNF-α and its inhibitors

TNF-α, a member of the TNF superfamily, is mainly produced by activated macrophages and lymphocytes [117]. After binding to two receptors, TNFRI and TNFRII, it can thereby lead to a variety of cellular and molecular behaviours and events [118]. TNF-α is a two-edged sword with the ability of promoting and inhibiting inflammatory response. On one hand, TNF-α can regulate
## Table 2: Major clinical studies on the efficacy and safety of tocilizumab in adult-onset Still’s disease

| Author, year (Refs) | Patient number | Dosage of tocilizumab | Overall response | Mean follow-up (months) | Severe adverse events | Study character |
|---------------------|----------------|-----------------------|------------------|-------------------------|-----------------------|-----------------|
| Puéchal X, 2011 [96] | 14             | 8 mg/kg/4 weeks (9)   | EULAR remission at 6 months: 8 (57.1%) resolved systemic symptoms: 6/7 (85.7%) Corticosteroid dosage ≤10 mg/day: 7 (50%) | <12                     | 0                      | Retrospective observational study |
|                     |                | 8 mg/kg/2 weeks (4)   |                 |                         |                       |                  |
|                     |                | 8 mg/kg/3 weeks (1)   |                 |                         |                       |                  |
|                     |                | 8 mg/kg/month (11)    |                 |                         |                       |                  |
| Suematsu R, 2012 [97] | 11             | 8 mg/kg/month (11)    | Remission without further flares: 10 (90.9%) Stopped steroids use: 2 (18.2%) | >12                     | 0                      | Retrospective multicentre observational study |
| Cipriani P, 2013 [98] | 11             | 8 mg/kg/4 weeks (11)  | EULAR (DAS28 < 2.6) remission at 6 months: 7/83.8% EULAR (DAS28 < 2.6) remission at 12 months: 9 (81.8%) Discontinued corticosteroid use: 8 (72.7%) Improvement of arthralgia: 13 (86.7%) Improvement of systemic symptoms: 15 (100%) Discontinued prednisone use: 9 (60%) | >12                     | 0                      | Retrospective case series |
| Elkayam O, 2014 [99] | 15             | 8 mg/kg/4 weeks (12)  | Improvement of arthralgia: 13 (86.7%) Improvement of systemic symptoms: 15 (100%) Discontinued prednisone use: 9 (60%) | >12                     | 0                      | Retrospective multicentre observational study |
|                     |                | 8 mg/kg/2 weeks (3)   |                 |                         |                       |                  |
| Ortiz-Sanjuán F, 2014 [100] | 34         | 8 mg/kg/4 weeks (22) | Improvement of arthritis 97.1% to 32.4% Improvement of skin rash 58.8% to 5.9% Improvement of fever 58.8% to 5.9% Improvement of lymphadenopathy 29.4% to 0% The median dosage of prednisone was also reduced. | >12                     | Severe infections (2) | Multicentre retrospective open label study |
|                     |                | 4 mg/kg/4 weeks (2)   |                 |                         |                       |                  |
|                     |                | 8 mg/kg/2 weeks (10)  |                 |                         |                       |                  |
| Bannai E, 2014 [101] | 7              | 8 mg/kg/2 weeks (6)   | Remission without further flares: 7 (100%) Stopped corticosteroid use: 1 (14.3%) | >12                     | MAS (2)               | Retrospective case series |
|                     |                | 8 mg/kg/2 weeks (1)   |                 |                         |                       |                  |
| Nishina N, 2015 [92] | 10             | 8 mg/kg/4 weeks (6)   | Improvement of systemic symptoms: 10 (100%) Improvement of arthralgia: 8 (80%) The median dose of glucocorticoids had been significantly reduced. | >12                     | 0                      | Retrospective case series |
|                     |                | 8 mg/kg/4 weeks (4)   |                 |                         |                       |                  |
| Song ST, 2016 [83]  | 22             | 8 mg/kg/4-5 weeks (18)| Good response at 6 months (modified Pouchot’s score decrease >2): 11 (50%) Good response at 12 months: 9 (64.3%) | <12                     | 0                      | Multicentre retrospective case series |
|                     |                | 6 mg/kg/4 weeks (2)   |                 |                         |                       |                  |
|                     |                | 4 mg/kg/4 weeks (2)   |                 |                         |                       |                  |
| Li T, 2017 [103]    | 8              | 8 mg/kg/4 weeks (5)   | After 6 months of follow-up, remission rates of fever: 6 (75%) remission rates of arthritis: 8 (100%) remission rates of rashes: 6 (75%) | <12                     | Hepatic dysfunction and coagulation function deterioration (1) | Multicentre prospective open label study |
|                     |                | (maximum 400 mg)      |                 |                         |                       |                  |
|                     |                | 4 mg/kg/4 weeks (4)   |                 |                         |                       |                  |
| Kaneko Y, 2018 [91] | 27             | 8 mg/kg/2 weeks (13), placebo (13) for 12 weeks, after then open study with 8 mg/kg/2 weeks until 52 weeks. | ACR50 response at week 12: 61.5% (TCZ) vs 30.8% (PBO) (P = 0.238) ACR70 response at week 12: 46.2% (TCZ) vs 30.8% (PBO) (P = 0.688) Decrease in systemic feature score from baseline at week 12: –4.1 (TCZ) vs –2.3 (PBO) (P = 0.033) Decrease in dose of prednisolone from baseline at week 12: 46.2% (TCZ) vs 21.0% (PBO) (P = 0.017) | >12                     | Serious infection (3) Anaphylactic shock (1) | Randomized, double-blind, placebo-controlled phase III trial |

MAS, macrophage activating syndrome; PBO, placebo; TCZ, tocilizumab.
leucocyte activation, maturation, cytokine and chemo-
kine release, production of reactive oxygen species, and
facilitate inflammatory response. On the other, it’s an
immunosuppressive mediator capable of inhibiting the
development of autoimmune diseases and tumorigen-
esis [119]. TNF-α level is significantly elevated in serum
and synovial membranes of patients with either systemic
or chronic AOSD [43,120]. Two classes of TNF-α block-
ers have a place currently in managing rheumatic dis-
 ease: the monoclonal anti-TNF antibodies, such as
infliximab and adalimumab, and the soluble TNF recep-
tor, etanercept. The anti-TNF agents, infliximab, adali-
mumab and etanercept have been approved by the FDA
for the treatment of RA. TNF inhibitors were the first
bDMARDs in treating SOJIA, but the experience is lim-
ited in treating AOSD.

In 2001, infliximab was first used in three patients with
chronic and active AOSD. It showed a prolonged effi-
cacy in the treatment of relapse of refractory AOSD
patients [121]. Remarkable improvements of clinical
manifestations and normalization of laboratory indices
were observed in all six AOSD patients with severe dis-
 ease activity after infliximab treatment [122]. In an ob-
servational study of 20 AOSD patients, ten patients
were treated with infliximab, five treated with etanercept
and five with both drugs. With treatment with infliximab,
four patients achieved complete remission and nine
achieved partial remission [123].

In an open-label study, 12 AOSD patients with active
arthritis refractory to DMARDs were enrolled to receive
etanercept and showed improvement in arthritis without
adverse event [124]. However, in an observational study
of 20 cases, most patients achieved partial response (7/
10) with etanercept treatment, while only one patient
achieved complete remission (1/10) [123]. The safety
and efficacy of adalimumab in AOSD remains uncertain,
because it is limited by small sample sizes and lack of
relevant trials [125,126].

**IL-18 and its inhibitors**

Similar to IL-1β, IL-18 is a pro-inflammatory cytokine
belonging to the IL-1 superfamily, and it is secreted by
monocytes, macrophages and dendritic cells [100]. After
cleavage of the precursor (pro-IL-18) by caspase-1, IL-
18 become an active form [65]. The mature IL-18 binds
to the IL-18 receptor α (IL-18Ra) and IL-18 receptor β
(IL-18Rβ) and leads to activation of downstream pro-
inflammatory signals in effector cells. IL-18 activity is
tightly regulated by natural IL-18 binding protein (IL-
18BP), which precludes IL-18 from binding to its cogn-
ate receptors [127].

The circulating level of unbound IL-18 (free IL-18) is
elevated in patients with AOSD during the active and
inactive phase of AOSD compared with other inflam-
atory situations, such as RA, SLE, AS and PsA. A
higher level of free IL-18 is found in patients with ac-
tive disease compared with inactive disease, indicating
that IL-18 is a potential biomarker for evaluation
disease activity of AOSD [128,129]. An extremely high
level of IL-18 is also found in AOSD patients with MAS
[130]. Due to its critical role in AOSD pathogenesis, IL-
18 inhibitor, tadekinig alfa, has emerged as a potential
therapeutic strategy for AOSD, and may have a par-
ticular indication in the forms of AOSD associated with
MAS.

**Tadekinig alfa**

Tadekinig alfa is a recombinant human IL-18 binding pro-
tein. Recently, a phase II, open-label clinical trial recruited
23 refractory AOSD patients with fever or CRP levels
≥10 mg/l. Patients received 80 mg (n = 10) or 160 mg
(n = 13) tadekinig alfa three times per week. One patient
receiving 160 mg tadekinig alfa dropped out due to an in-
jection site reaction. One (toxic optic neuropathy) of three
serious adverse events was possibly related to the use of
tadekinig alfa. At week 3, the response rate of either group
was 50%, and all non-responders receiving 80 mg tadekinig
alfa were up-titrated to 160 mg and still achieved no clinical
response, indicating a favourable efficacy of 80 mg tadeki-
ning alfa in AOSD patients [131]. Two AOSD patients were
reported to have achieved favourable outcomes after tade-
king alfa treatment. The levels of free IL-18 in serum
dropped to almost undetectable levels within 2 h after injec-
tion and continued low up to 48 h [132].

**Janus kinase inhibitors**

The cytoplasmic domain of both type I and type II cytokine
receptors binds to the Janus kinases (JAKs), including
TYK2, JAK1, JAK2 and JAK3 [133]. After binding their
receptors, several cytokines lead to further induction of in-
flammatory gene expression via JAK pathways, which am-
plify the loop of inflammatory signalling. Due to their
prominent effects on cytokine production and modulation of
immune response, JAK inhibitors have been a promising
therapeutic strategy in the treatment of inflammatory dis-
eases such as RA, SLE and SpA [134]. JAK inhibitors im-
pede the effect of IL-6, IL-10, IFN-γ, IFN-α and GM-CSF,
which are strongly implicated in the AOSD pathogenesis.

**Tofacitinib**

Tofacitinib (formerly CP-690550), a JAK1/JAK3 inhibitor,
is renowned for the first time as the first JAK inhibitor
tested in the clinic [135]. In 2019, tofacitinib was tested
in 14 patients with refractory AOSD for the first time
from a single centre in China. Seven AOSD patients
achieved complete remission with decrement of con-
comitant glucocorticoids, six patients achieved partial
remission and one relapsed when the prednisone dose
was reduced. It suggests that tofacitinib may be an al-
ternative in treating AOSD, particularly in those with
arthritis form [136].
**Baricitinib**

Baricitinib (formerly designated INCB028050), a JAK1/ JAK2 inhibitor, has shown its good efficacy and tolerability in active refractory RA [137]. The efficiency of baricitinib has been reported in a corticosteroid-dependent refractory AOSD patient for the first time in 2019 [138].

In conclusion, JAK inhibitors appear to be effective in AOSD due to cytokine inhibition, thus warranting further clinical trials. Nowadays, more selective JAK inhibitors are developed and will provide more therapeutic options for the treatment of AOSD.

**Other biologic agents**

**Abatacept**

Abatacept is a CTLA4 Ig fusion protein that blocks the interaction between CD28 and CD80/86, thus down-regulates T-cell activation, a potential pathogenetic role in AOSD. Furthermore, abatacept reduces the production of pro-inflammatory cytokines, including IFN-γ and IL-17 [139]. Some case reports have shown a successful use of abatacept in treating refractory AOSD, who were unresponsive to traditional DMARDs, anakinra and adalimumab [140,141]. Disruption CD28 co-stimulatory signalling by abatacept has specific immune-suppressive effect on T cells, making it a promising therapeutic strategy for AOSD, but more practices are still needed [140,141].

**Rituximab**

The role of B cells in AOSD remains to be determined. It’s possible that treatment targeting B cells might inhibit pro-inflammatory cytokine release mediated by T cell. Rituximab, a chimeric anti-CD20 monoclonal antibody can inhibit the activation of T cells and the production of pro-inflammatory cytokines [142]. It has been approved for treatment of RA. However, only a few case reports have highlighted the potential efficacy of rituximab in refractory AOSD patients [85, 143,144].

**Future treatment perspectives**

GM-CSF can up-regulate neutrophil properties, including survival, adhesion and trafficking, oxidative burst, phagocytosis, and formation of NETs [145–149]. As increased neutrophil count and NETs are key characteristics of AOSD [150,151], it will be of interest to see if treatment targeting GM-CSF or its receptor will be a new, highly effective way. GM-CSF binds to GM-CSF receptor α (GM-CSFRα), and then macrophage and neutrophil are enhanced in number and function in inflammatory lesions, resulting in excessive secretion of pro-inflammatory cytokines, including IL-1β, IL-6, IL-12, IL-23 and TNF [152–154]. There is increasing evidence that GM-CSF deletion/depletion has indicated encouraging efficacy and safety profiles in many inflammatory and autoimmune diseases, including RA, axial spondylarthritis and plaque psoriasis.

Mavrilimumab (formerly known as CAM-3001) is an IgG4 mAb that blocks GM-CSFRα directly, and otilimab (formerly known as MOR-103) is an IgG1 mAb that binds to GM-CSF and prevents its interaction with GM-CSFRα. In a phase Ib/IIa clinical trial, otilimab has preliminary evidence of clinical efficacy, and has a good safety and tolerability in patients with active RA [155]. In 2 phase Ib studies and an open-label extension study with a total of 442 RA patients, 65% of patients achieved remission with Disease Activity Score in 28 joints using the CRP level (DAS28-CRP <3.2, demonstrating the sustained efficacy of mavrilimumab [156]. In a 24-week, randomized phase Ib study, mavrilimumab and golimumab (anti-TNF) were demonstrated to be well-tolerated and had similar efficacy in RA patients who had an inadequate response to other previous treatments [157]. In a prospective cohort study in patients with severe COVID-19 pneumonia and hyperinflammation, mavrilimumab improved clinical outcomes in resolution of inflammation and mortality [158]. Mavrilimumab quenches downstream production of myriad pro-inflammatory mediators mediated by granulocytes and macrophages, indicating a potential efficacy in the treatment of AOSD.

**Conclusions**

A cytokine storm evoked mainly by macrophages and neutrophils is the hallmark of AOSD pathogenesis. As the role of cytokines in the pathogenesis of AOSD is gradually unveiled, new windows are opened for effective experimental treatments, especially for refractory cases. IL-1-targeted biologics and IL-6-targeted biologics are the major therapeutic agents in treating refractory AOSD now. New biologics against IL-18, TNF-α and GM-CSF and JAK inhibitors may become promising therapeutic options for AOSD. Because the incidence of AOSD is quite low, large collaborative projects are required to confirm the efficiency and safety of emerging biologics.

**Acknowledgements**

Y.M.: constructed the figures and the tables, and wrote the manuscript. J.M., J.J., M.W., J.T. and D.Z.: searched for articles. C.Y.: designed the review’s structure and revised the manuscript. Q.H.: designed the figures and tables and revised the manuscript. All authors contributed the review and approved the submitted version.

**Funding:** This work was supported by the National Natural Science Foundation of China (82001704), Shanghai Sailing Program (20YF1427100), Shanghai Science and Technology Innovation Action (20Y11911500).

**Disclosure statement:** The authors have declared no conflicts of interest.
References

1. Magadur-Joly G, Billaud E, Barrier JH et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 1995;54:587–90.

2. Wakai K, Ohta A, Tamakoshi A et al. Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol 1997;7:221–5.

3. Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still's disease in Northern Norway. Scand J Rheumatol 2006;35:48–51.

4. Mahroum N, Mahagna H, Amital H. Diagnosis and classification of adult Still's disease. J Autoimmun 2014;48–49:34–7.

5. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still's disease. Autoimmun Rev 2014;13:708–22.

6. Still GF. On a form of chronic joint disease in children. Med Chir Trans 1897;30:47–60.9.

7. Bywaters EG. Still's disease in the adult. Ann Rheum Dis 1971;30:121–3.

8. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. J Autoimmun 2018;93:24–36.

9. Cush JJ, Medsger TA, Herbert DC, Cooperstein LA. Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 1987;30:186–94.

10. Meng J, Ma Y, Jia J. Cytokine storm in coronavirus disease 2019 and adult-onset Still's disease: similarities and differences. Front Immunol 2021;11:603389.

11. Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 2013;61:345–8.

12. Ichida H, Kawaguchi Y, Sugiru T et al. Clinical manifestations of adult-onset Still's disease presenting with erosive arthritis: association with low levels of ferritin and Interleukin-18. Arthritis Care Res 2014;66:642–6.

13. Shimizu M, Yokoyama T, Yamada K et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology 2010;49:1645–53.

14. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 2008;4:34–42.

15. Jamilloux Y, Gerfaud-Valentin M, Martinon F et al. Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. Immunol Res 2015;61:53–62.

16. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011;7:416–26.

17. Mitrovic S, Fautrel B. New markers for adult-onset Still's disease. Joint Bone Spine 2018;85:285–93.

18. Jung J-Y, Suh C-H, Kim H-A. The role of damage-associated molecular pattern for pathogenesis and biomarkers in adult-onset Still's disease. Expert Rev Mol Diagn 2019;19:459–68.

19. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol 2018;14:603–18.

20. Hsieh C-W, Chen Y-M, Lin C-C et al. Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset Still disease. J Rheumatol 2017;44:1142–50.

21. Hu Q, Shi H, Zeng T et al. Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease. Arthritis Res Ther 2019;21:9.

22. Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 2006;6:940–52.

23. Vastert SJ, van Wijk R, D'Urbano LE et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology 2010;49:441–9.

24. Lee S-J, Cho Y-N, Kim T-J et al. Natural killer T cell deficiency in active adult-onset Still's Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells. Arthritis Rheum 2012;64:2868–77.

25. Park JH, Kim H-S, Lee JS et al. Natural killer cell cytolytic function in Korean patients with adult-onset Still's disease. J Rheumatol 2012;39:2000–7.

26. Shimojima Y, Kishida D, Ueno K-I et al. Characteristics of circulating natural killer cells and their interferon-γ production in active adult-onset Still disease. J Rheumatol 2019;46:1268–76.

27. Chen D-Y, Chen Y-M, Chen H-H et al. The associations of circulating CD4+CD25high regulatory T cells and TGF-β with disease activity and clinical course in patients with adult-onset Still's disease. Connect Tissue Res 2010;51:370–7.

28. Chen DY, Lan JL, Lin FJ et al. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 2004;63:1300–6.

29. Chen D-Y, Chen Y-M, Lan J-L et al. Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease. Rheumatology 2010;49:2305–12.

30. Mossmann TR, Coffman RL. Coffman RL TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145–73.

31. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity 2019;50:892–906.

32. Sun Y, Wang Z, Chi H et al. Elevated serum levels of interleukin-10 in adult-onset Still's disease are associated with disease activity. Clin Rheumatol 2019;38:3205–10.

33. Chi H, Liu D, Sun Y et al. Interleukin-37 is increased in adult-onset Still's disease and associated with disease activity. Arthritis Res Ther 2018;20:54.
Current and emerging biological therapy in adult-onset Still’s disease

34 Fiorentino DF, Zlotnik A, Mosmann TR et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815–22.

35 Ip WKE, Hoshi N, Shouval DS et al. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science 2017;356:513–9.

36 Kulkarni U, Karsten CM, Kohler T et al. IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration. J Allergy Clin Immunol 2016;137:1487–9.6.

37 Nold MF, Nold-Petry CA, Zepp JA et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010;11:1014–22.

38 Huang J, Hou FL, Zhang AY, Li ZL. Protective effect of the polarity of macrophages regulated by IL-37 on atherosclerosis. Genet Mol Res 2016;15:doi: 10.4238/gmr.15027616.

39 Shouval DS, Biswas A, Goettel JA et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity 2014;40:706–19.

40 Terkeltaub R, Esdaile JM, Décary F et al. HLA-Bw35 and prognosis in adult Still’s disease. Arthritis Rheum 1981;24:1469–72.

41 Pouchot J, Sampalis JS, Beaudet F et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine 1991;70:118–36.

42 Wouters JM, Reekers P, van de Putte LB. Adult-onset Still’s disease. Disease course and HLA associations. Arthritis Rheum 1986;29:415–8.

43 Fuji T, Nojima T, Yasuoka H et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease. Rheumatology 2001;40:1398–404.

44 Joung CI, Lee HS, Lee SW et al. Association between HLA-DR B1 and clinical features of adult onset Still’s disease in Korea. Clin Exp Rheumatol 2003;21:489–92.

45 Li Z, Liu H-L, Chen J et al. Association of interleukin 18 gene -607 (C/A) promoter polymorphisms with disease course in Chinese patients with adult-onset Still’s disease. Arthritis Rheum 2010;62:2530–5.

46 Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369–76.

47 Chen D-Y, Chen Y-M, Chen H-H et al. Functional association of interleukin 18 gene -607 (C/A) promoter polymorphisms with disease course in Chinese patients with adult-onset Still’s disease. J Rheumatol 2009;36:2284–9.

48 Wang F-F, Huang X-F, Shen N et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther 2013;15:R65.

49 Yashiro M, Furukawa H, Asano T et al. Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still’s disease. Medicine 2018;97:e13394.

50 Kim JJ, Kim J-K, Shim S-C et al. MEFV gene mutations and their clinical significance in Korean patients with adult-onset Still’s disease. Clin Exp Rheumatol 2013;31:60–3.

51 Wang M, Liu M, Jia J et al. Association of leukocyte immunoglobulin-like receptor A3 (ILIR3) with neutrophil activation and its susceptibility in adult-onset Still’s disease. Arthritis Rheumatol 2021;73:1033–43.

52 McGonagle D, Ramanan AV, Bridgewood C. Bridgewood C Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat Rev Rheumatol 2021;17:145–57.

53 Ohta A, Yamaguchi M, Tsunematsu T et al. Adult Still’s disease: a multicenter survey of Japanese patients. J Rheumatol 1990;17:1058–63.

54 Wouters JM, van der Veen J, van de Putte LB et al. Adult onset Still’s disease and viral infections. Ann Rheum Dis 1988;47:764–7.

55 Escudero FJ, Len O, Falco V et al. Rubella infection in adult onset Still’s disease. Ann Rheum Dis 2000;59:493–8.

56 van de Putte LB, Wouters JM. Adult-onset Still’s disease. Bailliere’s Clin Rheumatol 1991;5:263–75.

57 Agniiotri A, Ruff A, Gotterer L et al. Adult onset Still’s disease associated with infection and hemophagocytic lymphohistiocytosis. Case Rep Med 2016;2016:2071815.

58 Kádár J, Petrovicz E. Adult-onset Still’s disease. Best Pract Res Clin Rheumatol 2004;18:663–76.

59 Kalyoncu U, Solmaz D, Erim K et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still’s disease: data from a large multicenter cohort. J Autoimmun 2016;69:59–63.

60 Cavalli G, Franchini S, Aiello P et al. Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol 2015;44:309–14.

61 Franchini S, Dagna L, Salvo F et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum 2010;62:2530–5.

62 Sfriso P, Priori R, Valesini G et al. Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol 2016;35:1683–9.

63 Liu Z, Lv X, Tang G. Clinical features and prognosis of adult-onset Still’s disease: 75 cases from China. Int J Clin Exp Med 2015;8:16634–9.

64 Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013;39:1003–18.

65 Schett G, Dayer J-M, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol 2016;12:14–24.

66 Ben-Sasson SZ, Wang K, Cohen J, Paul WE. IL-1β strikingly enhances antigen-driven CD4 and CD8 T-cell responses. Cold Spring Harbor Symp Quant Biol 2013;78:117–24.

https://academic.oup.com/rheumatology
of a single disease entity. Pediatr Rheumatol Online J 2015;13:50.

82 Kedor C, Listing J, Zernicke J et al. Canakinumab for treatment of adult-onset Still's disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multi-centre, investigator-initiated trial. Ann Rheum Dis 2020; 79:1090–7.

83 Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol 2011;71:639–41.

84 Petryna O, Cush JJ, Effthymiou P. IL-1 Trap rilonacept in refractory adult onset Still's disease. Ann Rheum Dis 2012;71:2056–7.

85 Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset Still's disease with rituximab. Reumatismo 2016;68:159–62.

86 Belfeki N, Smiti Khanfir M, Said F et al. Successful treatment of refractory adult onset Still's disease with rituximab. Reumatismo 2016;68:2570–9.

87 Ilowite NT, Prather K, Lokhnygina Y et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014;66: 2570–9.

88 Scheller J, Chalaris A, Schmidt-Arras D et al. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878–88.

89 Chalaris A, Garbers C, Rabe B et al. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 2011;90: 484–94.

90 Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010;21:11–9.

91 Kishimoto T, Akira S, Narazaki M et al. Interleukin-6 family of cytokines and gp130. Blood 1995;86:1243–54.

92 Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235–8.

93 Weaver CT, Hatton RD, Mangan PR et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007:25: 821–52.

94 Iwamoto M, Nara H, Hirata D et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002;46:3388–9.

95 Puéchal X, DeBandt M, BertheLOT J-M et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res 2011;63:155–9.

96 Puechal X, DeBandt M, BertheLOT J-M et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res 2011;63:155–9.
Current and emerging biological therapy in adult-onset Still's disease

biologic agents: multicenter results in Japan. Mod Rheumatol 2012;22:712–9.

98 Cipriani P, Ruscitti P, Carubbi F et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol 2014;33:49–55.

99 Eliayam O, Jiries N, Dranitzi Z et al. Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol 2014;41:244–7.

100 Afonina IS, Müller C, Martin SJ et al. Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity 2015;42:991–1004.

101 Bannai E, Yamashita H, Kaneko S et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still’s disease. Mod Rheumatol 2016;26:297–301.

102 Kaneko Y, Kameda H, Ikeda K et al. Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 2018;77:1720–9.

103 Nishina N, Kaneko Y, Kameda H et al. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: a retrospective, single-center study. Mod Rheumatol 2015;25:401–4.

104 Song ST, Kim JJ, Lee S et al. Efficacy of tocilizumab therapy in Korean patients with adult-onset Still’s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol 2016;34:S64–S71.

105 de Boysson H, Février J, Nicolle A et al. Tocilizumab in the treatment of the adult-onset Still’s disease: current clinical evidence. Clin Rheumatol 2013;32:141–7.

106 Thonhofer R, Hiller M, Just H et al. Treatment of refractory adult-onset Still’s disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int 2011;31:1653–6.

107 Sakai R, Nagasawa H, Nishi E et al. Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol 2012;31:569–74.

108 Andrade-Ortega L, Irazoqui-Palazuelos F, Muñoz-López S et al. Efficacy of tocilizumab in refractory adult-onset Still’s disease: report of 2 cases. Reumatol Clin 2014;10:199–200.

109 Ortiz-Sanjuán F, Blanco R, Calvo-Rio V et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 2014;66:1659–65.

110 Li T, Gu L, Wang X et al. A pilot study on tocilizumab for treating refractory adult-onset Still’s disease. Sci Rep 2017;7:13477.

111 Watanabe E, Sugawara H, Yamashita T et al. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still’s disease: a case-based review. Case Rep Med 2016;2016:6568320.

112 Sumida K, Ubara Y, Hoshino J et al. Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol 2010;29:1191–4.

113 Kobayashi M, Takahashi Y, Yamashita H et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol 2011;21:92–6.

114 Kadavath S, Zapantis E, Zolty R et al. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still’s disease: targeting IL-6. Int J Rheum Dis 2014;17:336–40.

115 Simeni Njonnou SR, Soyfoo MS, Vanderheyst F-A. Efficacy of sarilumab in adult-onset Still’s disease as a corticosteroid-sparing agent. Rheumatology 2019;58:1878–9.

116 Emery P, von Hoogstraten H, Jayawardena S et al. Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab. Rheumatology 2018;57(Suppl 3):key075.446.

117 Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Reviews Drug Discovery 2010;9:482–93.

118 Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397–440.

119 Akdis M, Aab A, Altunbulakli C. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2016;138:984–1010.

120 Chen D-Y, Lan J-L, Lin F-J et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol 2004;31:2189–98.

121 Cavagna L, Caporalì E, Epis O et al. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol 2001;19:329–32.

122 Kraetsch HG, Antoni C, Kalden JR et al. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Annals Rheum Dis 2001;60(Suppl 3):iii55–7.

123 Fautrel B, Sibilia J, Mariette X et al. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis 2005;64:262–6.

124 Husni ME, Maier AL, Mease PJ et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum 2002;46:1171–6.

125 Bencucci M, Li GF, Del Rosso A et al. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still’s disease: the first case report. Clin Exp Rheumatol 2005;23:733.

126 Rech J, Ronneberger M, Engbrecht M et al. Successful treatment of adult-onset Still’s disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis 2011;70:390–2.

127 Chauhan D, Vande Walle L, Lamkanfi M. Therapeutic modulation of inflammasome pathways. Immunol Rev 2020;297:123–38.
128 Girard C, Rech J, Brown M et al. Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology 2016;55:2237–47.

129 Jung KH, Kim JH, Lee JS et al. Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still’s disease. Scand J Rheumatol 2014;43:162–9.

130 Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 2010;37:967–73.

131 Gabay C, Fautrel B, Rech J et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadeking alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 2018;77:840–7.

132 Kiltz U, Kiefer D, Braun J et al. Prolonged treatment with Tadeking alfa in adult-onset Still’s disease. Ann Rheum Dis 2020;79:e10.

133 Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293–322.

134 Schwartz DM, Kanno Y, Villarino A et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;17:78.

135 O’Shea JJ, Kontizas A, Yamaoka K et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72 Suppl 2:i111–5.

136 Hu Q, Wang M, Jia J et al. Tofacitinib in refractory adult onset Still’s disease: 14 cases from a single centre in China. Ann Rheum Dis 2020;79:842–4.

137 Keystone E, Taylor P, Genovese M et al. Genovese M 12-Week results of a Phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK/JAK2 inhibitor, in combination with traditional DMARDs in patients with rheumatoid arthritis. Ann Rheum Dis 2013;71:152–3.

138 Ladhari C, Jorgensen C, Pers Y-M. Treatment of refractory adult onset Still’s disease with combination anakinra and baricitinib therapy. Rheumatology 2019;58:736–7.

139 Platt AM, Gibson VB, Patakas A et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010;185:1558–67.

140 Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still’s disease. Clin Exp Rheumatol 2010;28:265–7.

141 Ostrowski RA, Tehrani R, Kadanoff R, Kadanoff R. Refractory adult-onset Still’s disease successfully treated with abatacept. J Clin Rheumatol 2011;17:315–7.

142 Dörner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 2003;15:246–52.

143 Bartoloni E, Alunno A, Luccioni F. Successful treatment of refractory adult-onset Still’s disease with anti-CD20 monoclonal antibody. Clin Exp Rheumatol 2009;27:888–9.

144 Padilla-Ibarra J, Sanchez-Ortiz A, Sandoval-Castro C, Ramos-Remus C. Rituximab treatment for pulmonary arterial hypertension in adult-onset Still’s disease. Clin Exp Rheumatol 2013;31:657–8.

145 Yong KL, Rowles PM, Patterson KG et al. Granulocyte-macroage colony-stimulating factor induces neutrophil adhesion to pulmonary vascular endothelium in vivo: role of beta 2 integrins. Blood 1992;80:1565–75.

146 Yousefi S, Mihalache C, Kozlowski E et al. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. Cell Death Differ 2009;16:1438–44.

147 Cowburn AS, Summers C, Dunmore BJ et al. Granulocyte/macroage colony-stimulating factor causes a paradoxical increase in the BH3-only pro-apoptotic protein Bim in human neutrophils. Am J Respir Cell Mol Biol 2011;44:879–87.

148 Goldmann O, Medina E. The expanding world of extracellular traps: not only neutrophils but much more. Front Immunol 2012;3:420.

149 Wright HL, Thomas HB, Moots RJ et al. RNA-seq reveals activation of both common and cytokine-specific pathways following neutrophil priming. PLoS one 2013;8:e85858.

150 Jia J, Yang L, Cao Z et al. Neutrophil-derived lipocalin-2 in adult-onset Still’s disease: a novel biomarker of disease activity and liver damage. Rheumatology 2021;60:304–15.

151 Jia J, Wang M, Ma Y et al. Circulating neutrophil extracellular traps signature for identifying organ involvement and response to glucocorticoid in adult-onset Still’s disease: a machine learning study. Front Immunol 2020;11:56335.

152 Greven DEA, Cohen ES, Gerlag DM et al. Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis. Ann Rheum Dis 2015;74:1924–30.

153 Cook AD, Louis C, Robinson MJ et al. Granulocyte macroage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation. Arthritis Res Ther 2016;18:287.

154 Hamilton JA. GM-CSF in inflammation. J Exp Med 2020;217:e20190945.

155 Behrens F, Tak PP, Østergaard M et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 2015;74:1058–64.

156 Burmester GR, McNees IB, Kremer JM et al. Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis. Arthritis Rheumatol 2018;70:679–89.

157 Weinblatt ME, McNees IB, Kremer JM et al. A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis. Arthritis Rheumatol 2018;70:49–59.

158 De Luca G, Cavalli G, Campochiaro C et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol 2020;2:e465–e473.